NRX Pharmaceuticals Files 8-K
Ticker: NRXPW · Form: 8-K · Filed: Dec 29, 2025 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Dec 29, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $5.4 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing
TL;DR
NRX Pharma filed an 8-K on Dec 29th, reporting a Dec 18th event. Old name: Big Rock Partners Acquisition Corp.
AI Summary
NRX Pharmaceuticals, Inc. filed an 8-K on December 29, 2025, reporting an event on December 18, 2025. The filing indicates the company's incorporation in Delaware and its standard industrial classification as Pharmaceutical Preparations. It also lists its former name as Big Rock Partners Acquisition Corp., with a name change date of October 12, 2017.
Why It Matters
This 8-K filing provides an update on NRX Pharmaceuticals, Inc., including its corporate structure and history, which is important for investors and stakeholders to track company developments.
Risk Assessment
Risk Level: low — This filing is primarily administrative and informational, with no immediate financial or operational risks disclosed.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- December 18, 2025 (date) — Earliest event reported
- December 29, 2025 (date) — Filing date
- Big Rock Partners Acquisition Corp. (company) — Former company name
- October 12, 2017 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing for NRX Pharmaceuticals, Inc.?
The 8-K filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting an event that occurred on December 18, 2025.
When was NRX Pharmaceuticals, Inc. incorporated and in which jurisdiction?
NRX Pharmaceuticals, Inc. was incorporated in Delaware.
What was NRX Pharmaceuticals, Inc.'s former company name?
The former company name was Big Rock Partners Acquisition Corp.
On what date did the company change its name from Big Rock Partners Acquisition Corp.?
The date of the name change was October 12, 2017.
What is NRX Pharmaceuticals, Inc.'s Standard Industrial Classification (SIC) code?
NRX Pharmaceuticals, Inc.'s Standard Industrial Classification is Pharmaceutical Preparations [2834].
Filing Stats: 562 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-12-29 16:30:18
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 pershare NRXP The Nasdaq Stock Mark
- $5.4 million — g that the Company repaid the remaining $5.4 million balance sheet debt to Anson Funds, LLC,
Filing Documents
- nrxp20251229_8k.htm (8-K) — 40KB
- ex_902938.htm (EX-99.1) — 10KB
- ex_902939.htm (EX-99.2) — 53KB
- ansonlogo.jpg (GRAPHIC) — 6KB
- nrxlogoleft.jpg (GRAPHIC) — 3KB
- 0001437749-25-038835.txt ( ) — 269KB
- nrxp-20251218.xsd (EX-101.SCH) — 4KB
- nrxp-20251218_def.xml (EX-101.DEF) — 13KB
- nrxp-20251218_lab.xml (EX-101.LAB) — 17KB
- nrxp-20251218_pre.xml (EX-101.PRE) — 13KB
- nrxp20251229_8k_htm.xml (XML) — 5KB
01
Item 7.01 Regulation FD Disclosure. On December 18, 2025, NRx Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the Company repaid the remaining $5.4 million balance sheet debt to Anson Funds, LLC, through equity conversion of common stock and has eliminated all balance sheet debt following the conversion. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this "Form 8-K") and is incorporated by reference hereto. The information furnished with this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated December 18, 2025 99.2 Debt Cancellation Agreement / Pay-Off Letter 104 Cover Page Interactive Data File (embedded with the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. NRx Pharmaceuticals, Inc. Date: December 29, 2025 By: /s/ Jonathan Javitt Name: Jonathan Javitt Its: Interim Chief Executive Officer